Patient and treatment characteristics of all 2263 patients and according to TDT groups
| Parameter . | All patients, n = 2263 . | TDT, 0-5 d; n = 1547 . | TDT, 6-10 d; n = 447 . | TDT, 11-15 d; n = 106 . | TDT, >15 d; n = 163 . |
|---|---|---|---|---|---|
| Age at initial diagnosis, y | |||||
| Mean (SD) | 57.40 (13.73) | 56.45 (13.97) | 59.64 (12.81) | 60.05 (12.49) | 58.52 (13.69) |
| Median (IQR) | 59 (50-68) | 58 (49-67) | 61 (53-69) | 63 (54-69) | 60 (51-69) |
| Female sex, no./no. available (%) | 1036/2263 (45.8) | 735/1547 (47.5) | 193/447 (43.2) | 39/106 (36.8) | 69/163 (42.3) |
| AML type, no./no. available (%) | |||||
| De novo AML | 1691/2255 (75.0) | 1224/1545 (79.2) | 302/444 (68.0) | 72/106 (67.9) | 93/160 (58.1) |
| sAML | 341/2255 (15.1) | 177/1545 (11.5) | 90/444 (20.3) | 24/106 (22.6) | 50/160 (31.2) |
| tAML | 223/2255 (9.9) | 144/1545 (9.3) | 52/444 (11.7) | 10/106 (9.4) | 17/160 (10.6) |
| ECOG status 0-1 | 1891/2255 (85.4) | 1278/1513 (84.5) | 389/438 (88.8) | 86/104 (82.7) | 138/159 (86.8) |
| HCT-CI score 0-2 | 1746/2263 (77.2) | 1209/1547 (78.2) | 337/447 (75.4) | 75/106 (70.8) | 125/163 (76.7) |
| WBC, ×109/L | |||||
| Mean (SD) | 32.19 (52.86) | 38.65 (56.47) | 20.21 (43.92) | 12.2 (23.86) | 16.3 (39.64) |
| Median (IQR) | 8.00 (2.2-39.23) | 14.12 (2.6-52.75) | 3.8 (1.9-19) | 3.15 (1.76-9.68) | 3.16 (1.7-10.5) |
| HL,* no./no. available (%) | 465/2239 (20.8) | 398/1535 (25.9) | 44/437 (10.1) | 7/106 (6.6) | 16/161 (9.9) |
| LDH,U/L | |||||
| Mean (SD) | 598 (712) | 664 (792) | 463 (485) | 431 (346) | 422 (459) |
| Median (IQR) | 396 (249-654) | 443 (282-724) | 318 (228-514) | 280 (218-505) | 252 (199-483) |
| Bone marrow blasts (%) | |||||
| Mean (SD) | 58.01 (24.81) | 61.91 (24.21) | 52.76 (23.39) | 46.59 (23.45) | 40.72 (23.68) |
| Median (IQR) | 60 (36-80) | 68 (40-81) | 50 (33-70) | 45 (30-66) | 33 (24-60) |
| TDT, d | |||||
| Mean (SD) | 5.65 (6.47) | 2.6 (1.28) | 7.61 (1.32) | 12.75 (1.37) | 24.67 (8.13) |
| Median (IQR) | 3 (2-7) | 2 (2-4) | 8 (6-9) | 13 (11-14) | 22 (18-30) |
| Treatment regimen, no./no. available (%) | |||||
| 7+3 | 2186/2263 (96.6) | 1509/1547 (97.5) | 428/447 (95.7) | 101/106 (95.3) | 148/163 (90.8) |
| HAM | 61/2263 (2.7) | 28/1547 (1.8) | 16/447 (3.6) | 4/106 (3.8) | 13/163 (8) |
| HiDAC/IDAC | 16/2263 (0.7) | 10/1547 (0.6) | 3/447 (0.7) | 1/106 (0.9) | 2/146 (1.2) |
| Allogeneic SCT in CR1 | 440/2263 (19.4) | 304/1547 (19.7) | 90/447 (20.1) | 17/106 (16) | 29/163 (17.8) |
| Allogeneic SCT salvage | 759/2263 (33.5) | 549/1547 (35.5) | 130/447 (29.1) | 30/106 (28.3) | 50/163 (30.7) |
| ELN risk 2017 group, no./no. available (%) | |||||
| Favorable | 546/2049 (26.6) | 410/1401 (29.3) | 98/402 (24.4) | 15/96 (15.6) | 23/150 (15.3) |
| Intermediate | 1104/2049 (53.9) | 724/1401 (51.7) | 217/402 (54) | 59/96 (61.5) | 104/150 (69.3) |
| Adverse | 399/2049 (19.5) | 267/1401 (19.1) | 87/402 (21.6) | 22/96 (22.9) | 23/150 (15.3) |
| Karyotype, no./no. available (%) | |||||
| Abnormal, including complex | 995/2061 (48.3) | 672/1411 (47.6) | 209/404 (51.7) | 47/96 (49) | 67/150 (44.7) |
| Complex | 285/2061 (13.8) | 188/1411 (13.3) | 64/404 (15.8) | 18/96 (18.8) | 15/150 (10) |
| NPM1 mutated | 587/2047 (28.7) | 447/1428 (31.3) | 97/398 (24.4) | 16/89 (18) | 27/132 (20.5) |
| FLT3-ITD mutation | 391/1990 (19.6) | 311/1381 (22.5) | 52/395 (13.2) | 12/90 (13.3) | 16/124 (12.9) |
| FLT3-ITD ratio | |||||
| Mean (SD) | 1.37 (6.35) | 1.37 (6.63) | 1.13 (4.48) | 0.46 (0.34) | 3.15 (8.39) |
| Median (IQR) | 0.5 (0.24-0.8) | 0.52 (0.29-0.82) | 0.37 (0.11-0.6) | 0.39 (0.2-0.76) | 0.46 (0.28-0.66) |
| HU pretreatment, no./no. available (%) | 95/2263 (4.2) | 69/1547 (4.5) | 19/447 (4.3) | 4/106 (3.8) | 3/163 (1.8) |
| Parameter . | All patients, n = 2263 . | TDT, 0-5 d; n = 1547 . | TDT, 6-10 d; n = 447 . | TDT, 11-15 d; n = 106 . | TDT, >15 d; n = 163 . |
|---|---|---|---|---|---|
| Age at initial diagnosis, y | |||||
| Mean (SD) | 57.40 (13.73) | 56.45 (13.97) | 59.64 (12.81) | 60.05 (12.49) | 58.52 (13.69) |
| Median (IQR) | 59 (50-68) | 58 (49-67) | 61 (53-69) | 63 (54-69) | 60 (51-69) |
| Female sex, no./no. available (%) | 1036/2263 (45.8) | 735/1547 (47.5) | 193/447 (43.2) | 39/106 (36.8) | 69/163 (42.3) |
| AML type, no./no. available (%) | |||||
| De novo AML | 1691/2255 (75.0) | 1224/1545 (79.2) | 302/444 (68.0) | 72/106 (67.9) | 93/160 (58.1) |
| sAML | 341/2255 (15.1) | 177/1545 (11.5) | 90/444 (20.3) | 24/106 (22.6) | 50/160 (31.2) |
| tAML | 223/2255 (9.9) | 144/1545 (9.3) | 52/444 (11.7) | 10/106 (9.4) | 17/160 (10.6) |
| ECOG status 0-1 | 1891/2255 (85.4) | 1278/1513 (84.5) | 389/438 (88.8) | 86/104 (82.7) | 138/159 (86.8) |
| HCT-CI score 0-2 | 1746/2263 (77.2) | 1209/1547 (78.2) | 337/447 (75.4) | 75/106 (70.8) | 125/163 (76.7) |
| WBC, ×109/L | |||||
| Mean (SD) | 32.19 (52.86) | 38.65 (56.47) | 20.21 (43.92) | 12.2 (23.86) | 16.3 (39.64) |
| Median (IQR) | 8.00 (2.2-39.23) | 14.12 (2.6-52.75) | 3.8 (1.9-19) | 3.15 (1.76-9.68) | 3.16 (1.7-10.5) |
| HL,* no./no. available (%) | 465/2239 (20.8) | 398/1535 (25.9) | 44/437 (10.1) | 7/106 (6.6) | 16/161 (9.9) |
| LDH,U/L | |||||
| Mean (SD) | 598 (712) | 664 (792) | 463 (485) | 431 (346) | 422 (459) |
| Median (IQR) | 396 (249-654) | 443 (282-724) | 318 (228-514) | 280 (218-505) | 252 (199-483) |
| Bone marrow blasts (%) | |||||
| Mean (SD) | 58.01 (24.81) | 61.91 (24.21) | 52.76 (23.39) | 46.59 (23.45) | 40.72 (23.68) |
| Median (IQR) | 60 (36-80) | 68 (40-81) | 50 (33-70) | 45 (30-66) | 33 (24-60) |
| TDT, d | |||||
| Mean (SD) | 5.65 (6.47) | 2.6 (1.28) | 7.61 (1.32) | 12.75 (1.37) | 24.67 (8.13) |
| Median (IQR) | 3 (2-7) | 2 (2-4) | 8 (6-9) | 13 (11-14) | 22 (18-30) |
| Treatment regimen, no./no. available (%) | |||||
| 7+3 | 2186/2263 (96.6) | 1509/1547 (97.5) | 428/447 (95.7) | 101/106 (95.3) | 148/163 (90.8) |
| HAM | 61/2263 (2.7) | 28/1547 (1.8) | 16/447 (3.6) | 4/106 (3.8) | 13/163 (8) |
| HiDAC/IDAC | 16/2263 (0.7) | 10/1547 (0.6) | 3/447 (0.7) | 1/106 (0.9) | 2/146 (1.2) |
| Allogeneic SCT in CR1 | 440/2263 (19.4) | 304/1547 (19.7) | 90/447 (20.1) | 17/106 (16) | 29/163 (17.8) |
| Allogeneic SCT salvage | 759/2263 (33.5) | 549/1547 (35.5) | 130/447 (29.1) | 30/106 (28.3) | 50/163 (30.7) |
| ELN risk 2017 group, no./no. available (%) | |||||
| Favorable | 546/2049 (26.6) | 410/1401 (29.3) | 98/402 (24.4) | 15/96 (15.6) | 23/150 (15.3) |
| Intermediate | 1104/2049 (53.9) | 724/1401 (51.7) | 217/402 (54) | 59/96 (61.5) | 104/150 (69.3) |
| Adverse | 399/2049 (19.5) | 267/1401 (19.1) | 87/402 (21.6) | 22/96 (22.9) | 23/150 (15.3) |
| Karyotype, no./no. available (%) | |||||
| Abnormal, including complex | 995/2061 (48.3) | 672/1411 (47.6) | 209/404 (51.7) | 47/96 (49) | 67/150 (44.7) |
| Complex | 285/2061 (13.8) | 188/1411 (13.3) | 64/404 (15.8) | 18/96 (18.8) | 15/150 (10) |
| NPM1 mutated | 587/2047 (28.7) | 447/1428 (31.3) | 97/398 (24.4) | 16/89 (18) | 27/132 (20.5) |
| FLT3-ITD mutation | 391/1990 (19.6) | 311/1381 (22.5) | 52/395 (13.2) | 12/90 (13.3) | 16/124 (12.9) |
| FLT3-ITD ratio | |||||
| Mean (SD) | 1.37 (6.35) | 1.37 (6.63) | 1.13 (4.48) | 0.46 (0.34) | 3.15 (8.39) |
| Median (IQR) | 0.5 (0.24-0.8) | 0.52 (0.29-0.82) | 0.37 (0.11-0.6) | 0.39 (0.2-0.76) | 0.46 (0.28-0.66) |
| HU pretreatment, no./no. available (%) | 95/2263 (4.2) | 69/1547 (4.5) | 19/447 (4.3) | 4/106 (3.8) | 3/163 (1.8) |
7+3, induction treatment with standard-dose cytarabine for 7 d and daunorubicin for 3 d; CR1, first complete remission; ECOG, clinical performance status according to ECOG criteria, comorbidities according to HCT-CI score; HAM, high-dose cytarabine plus mitoxantrone; HiDAC/IDAC, high-dose/intermediate-dose cytarabine; IQR, interquartile range; sAML, secondary AML; SD, standard deviation; tAML, treatment-related AML.
HL as defined by WBC >50 × 109/L at initial diagnosis.